Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Insights - The company's overall performance in 2025 showed strong resilience supported by its beer business, while the liquor business faced short-term pressure due to industry adjustments. The total revenue for 2025 was CNY 37.985 billion, a slight decrease of 1.68% year-on-year. The net profit attributable to shareholders was CNY 3.371 billion, down 28.87% year-on-year, primarily due to a goodwill impairment of CNY 28.77 billion related to the liquor business. Excluding this impairment and other special items, the adjusted net profit was CNY 5.724 billion, representing a year-on-year growth of 19.6% [6] Financial Performance Summary - In 2025, the beer business generated revenue of CNY 36.49 billion, remaining stable year-on-year, with sales volume reaching 11.03 million kiloliters, an increase of 1.4%. The average price per ton was CNY 3,308, down 1.4% year-on-year. The gross margin for the beer business improved by 1.4 percentage points to 42.5%, with adjusted EBITDA reaching CNY 9.611 billion, a growth of 17.4% year-on-year [6] - The liquor business faced significant challenges, with revenue of CNY 1.496 billion in 2025, a decline of 30.39% year-on-year. The company recognized a goodwill impairment of CNY 28.77 billion, which, while negatively impacting current profits, alleviated market concerns regarding the potential risks associated with goodwill [6] - The company achieved a gross margin of 43.07% in 2025, an increase of 0.43 percentage points year-on-year. The selling expense ratio decreased by 1.36 percentage points to 20.33%, leading to an improvement in the net profit margin (adjusted) by 2.75 percentage points to 15.07% [6] Earnings Forecast and Valuation - The forecasted net profit attributable to shareholders for 2026-2028 is CNY 6.009 billion, CNY 6.342 billion, and CNY 6.567 billion, with year-on-year growth rates of 78.3%, 5.5%, and 3.5%, respectively. The corresponding P/E ratios are projected to be 11.93, 11.3, and 10.92 times [6][7]

1. Report's Industry Investment Rating - No information about the industry investment rating is provided in the report. 2. Core Viewpoints of the Report - In Q4 2025, China's enterprise annuity showed the characteristics of continuous scale expansion and a decline in the investment return rate on a quarterly basis. The scale indicators such as the number of enterprises, the number of insured employees, and the accumulated funds increased steadily. The trustee market remained dominated by insurance funds, with a high concentration at the top. The bank - affiliated institutions rose rapidly but their share decreased slightly. The number of small and medium - sized enterprises establishing enterprise annuity plans may be increasing. The leading effect of investment management institutions was further strengthened, with the average management scale of insurance funds higher than that of public funds. The investment return rates of equity - containing annuity portfolios, fixed - income annuity portfolios, and pension products in Q4 2025 all declined significantly compared with Q3, but all types of investments achieved positive returns in 2025, and the annuity market maintained a stable development trend [2]. 3. Summary by Relevant Catalogs 3.1 Enterprise Annuity Coverage and Yield - As of Q4 2025, the number of established enterprises increased by 2,730 to 178,000, the number of participating employees increased by 109,400 to 33.43 million, and the accumulated funds increased by 0.12 trillion yuan to 4.21 trillion yuan. Only the number of single - plan (corporate entrustment) increased by 14, while other types remained stable. The investment - end scale increased steadily in Q4 2025, with the net value of investment assets increasing by 106.1 billion yuan and the number of portfolios increasing by 61. The cumulative return rate in the past three years rose slightly from 12.08% in Q3 2025 to 12.94%. On the benefit - receiving end, the number of recipients increased slightly by 266,400 to 3.6882 million in 2025, and the receiving amount increased by 7.164 billion yuan to 116.213 billion yuan. The per - capita receiving amount decreased from 31,900 yuan in 2024 to 31,500 yuan in 2025 [2]. 3.2 Trustee Market of Enterprise Annuity - **Trustee management asset amount**: The overall scale continued to rise, with a quarterly increase of 3.1% to 3.2 trillion yuan in Q4 2025. Institutions with relatively smaller trustee scales expanded relatively faster. China Life Pension (959.7 billion yuan), Ping An Pension (618.2 billion yuan), and Industrial and Commercial Bank of China (373.4 billion yuan) ranked in the top three in terms of trustee scale. The trustee asset scales of PICC Pension, CITIC Trust, and China Merchants Bank increased by 14.2%, 4.9%, and 4.8% respectively in Q4 2025. The share of bank - affiliated institutions decreased from 25.0% in Q3 2025 to 24.8% in Q4 2025 [2]. - **Number of enterprises managed by trustee institutions**: The total number of enterprises managed by enterprise annuity trustee institutions continued to grow, increasing by 2,223 to about 162,000 in Q4 2025 compared with Q3 2025, a quarterly increase of 1.4%. Insurance institutions continued to dominate the market, with the number of enterprises managed by insurance institutions accounting for 68.1% in Q4 2025, a decrease of 1.16 percentage points compared with Q3 2025. China Life Pension led with 43,000 managed enterprises, accounting for 26.7% of the whole market. In terms of quarterly growth rate, the number of enterprises managed by PICC Pension increased by 20.6% to 2,702 in Q4 2025, leading the industry. The number of enterprises managed by Industrial and Commercial Bank of China increased by 1,538 to 21,000 in Q4 2025, with rapid business growth [2]. - **Number of employees managed by trustee institutions**: The leading concentration effect was obvious, and the overall pattern was still dominated by insurance funds. The number of employees increased slightly by 0.6% to 27.59 million in Q4 2025. The number of small and medium - sized enterprises establishing enterprise annuity plans may be increasing. The number of employees managed by PICC Pension and CITIC Trust increased by 10.9% and 9.3% respectively to 495,000 and 222,000 in Q4 2025, much higher than their peers. Although the number of enterprises managed by Industrial and Commercial Bank of China and Bank of China increased significantly, the number of employees they managed increased by only 0.8% and 1.6% respectively, indicating that their new enterprise customers may be mostly small and medium - sized enterprises [2][3]. 3.3 Investment Management Institutions of Enterprise Annuity - In Q4 2025, the list of the top ten institutions in terms of portfolio asset amount was relatively stable. Taikang Asset, China Life Pension, and ICBC Credit Suisse ranked in the top three in terms of management scale with 715.4 billion yuan, 525.2 billion yuan, and 395.2 billion yuan respectively. The average management asset amount of public fund companies (153.6 billion yuan, an increase of 4.1 billion yuan compared with Q3 2025, a quarterly increase of 2.72%) was less than that of insurance institutions (an average of 291 billion yuan, an increase of 7.9 billion yuan compared with Q3 2025, a quarterly increase of 2.78%). In terms of scale changes, ICBC Credit Suisse, Taikang Asset, and Guotai Fund ranked in the top three in terms of increment, with increases of 24.8 billion yuan, 22 billion yuan, and 13.1 billion yuan respectively compared with Q3 2025. Guotai Fund, Xinhua Pension, and ICBC Credit Suisse ranked in the top three in terms of growth rate, with quarterly increases of 10.16%, 10.13%, and 6.7% respectively. ICBC Credit Suisse entered the top three in management scale (an increase of 1 place compared with Q3 2025) [3]. 3.4 Investment Performance - In Q4 2025, the investment return rates of equity - containing portfolios and fixed - income portfolios both declined compared with Q3 2025. The investment return rate of fixed - income portfolios decreased slightly by 0.29 percentage points (from 0.90% to 0.61%), mainly affected by the decline in the income of collective plans. The investment return rate of equity - containing portfolios declined significantly on a quarterly basis due to the high base in Q3 2025, with the single - quarter return rate falling from 4.82% to 0.8%. All plan types recorded a decline of more than 3.5 percentage points, which also drove the overall return rate to fall from 4.26% to 0.75%, with the single - quarter return rate of single - plans declining the most. In terms of the annual return rate in 2025, the return rates of fixed - income, equity - containing, and overall were 2.99%, 7.09%, and 6.51% respectively [3]. 3.5 Changes in Pension Products - Compared with Q3 2025, the scale of pension products decreased slightly and the overall return rate declined in Q4 2025. As of the end of 2025, there were 567 actually operating products, 1 less than in Q3 2025. The net asset value of equity products increased by 4.6% to 233.9 billion yuan on a quarterly basis, and the quarterly investment return rate fell from 22.9% in Q3 2025 to 2.0% in Q4 2025. The annual return rate in 2025 was 30.9%. The single - quarter return rates of ordinary stock - type and Hong Kong - stock - type products in Q4 2025 were 2.2% and 0.6% respectively, and the annual return rates were 29.5% and 44.9% respectively. The cumulative return rate of Hong Kong - stock products since their establishment recovered to - 9.6% in Q4 2025. The net asset value of fixed - income products decreased by 4.6% to 1,523.3 billion yuan on a quarterly basis, and the return rate in Q4 2025 slightly decreased to 0.5% (0.7% in Q3 2025). The annual return rate in 2025 was 2.7%. Overall, the total net asset value of pension products decreased slightly by 1.37% to 2,431 billion yuan on a quarterly basis, and the quarterly investment return rate fell from 3.1% in Q3 2025 to 0.7% in Q4 2025. The annual return rate in 2025 was 5.6% [3].

Investment Rating - The report maintains a "Positive" investment rating for the humanoid robot industry [4] Core Insights - Yushu Technology's IPO has been accepted, aiming to become the first humanoid robot company listed on A-shares. The company focuses on the research, production, and sales of quadrupedal and humanoid robots, with expected shipments exceeding 5,500 units in 2025, leading the global market. The company anticipates revenues of 1.71 billion yuan in 2025, a 335% increase year-on-year, and a net profit of 600 million yuan, reflecting a 674% increase [4][5][13][14] - The domestic humanoid robot industry is experiencing accelerated capitalization, with multiple companies undergoing IPO preparations and significant financing activities. The Ministry of Industry and Information Technology projects a shipment of approximately 14,400 units in 2025, with expectations for substantial growth in 2026 [5][44][45] - Tesla has clarified its production schedule for the Optimus humanoid robot, with mass production expected to begin in summer 2026, aiming for over 50,000 units produced by 2026 and a tenfold increase by 2027 [6][52] Summary by Sections Domestic Market - The domestic humanoid robot industry is witnessing a rapid capital influx, with 14 financing rounds exceeding 1 billion yuan in 2026 alone. Companies like Yushu Technology and others are actively pursuing IPOs and capital expansion [5][44] - The Ministry of Industry and Information Technology forecasts that the number of humanoid robot manufacturers in China will exceed 140 by 2025, with a market size reaching 1.55 billion yuan [45][47] - Local governments are providing substantial subsidies for core component development and technology innovation in the humanoid robot sector [49][50] International Market - Tesla's production timeline for the Optimus robot is becoming clearer, with expectations for mass production to start in summer 2026 and public sales by the end of 2027 [52] - The GTC 2026 event highlighted advancements in Physical AI, showcasing numerous robots and emphasizing the shift towards integrating AI in physical applications [54][58] Component Supply Chain - Key components such as joint modules and structural parts are expected to benefit from cost advantages, with companies like Changying Precision and Top Group leading the supply chain [8][74] - The report identifies several companies in the upstream supply chain that are well-positioned to capitalize on the growth of the humanoid robot market [74] Financial Performance - Yushu Technology's financial performance is robust, with a projected revenue of 1.71 billion yuan and a net profit margin of 37% in 2025. The company has seen significant growth in both humanoid and quadrupedal robot sales [14][18][20] - The report notes a shift in revenue sources, with humanoid robots becoming the largest revenue contributor, surpassing quadrupedal robots for the first time [18][20] Future Outlook - The humanoid robot industry is approaching a critical point of commercialization and standardization, with expectations for significant advancements in production capabilities and market applications in 2026 [10][74] - The report suggests that investors should focus on upstream components and leading manufacturers as the industry matures and scales [74]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing continuous expansion in its snack retail stores, leading to a steady improvement in profitability [5][7] - The company has a strong growth forecast, with significant revenue and profit increases projected for the coming years [6][7] Financial Performance Summary - In 2025, the company achieved a revenue of 51,459 million RMB, representing a year-on-year growth of 59.17% [7] - The net profit attributable to the parent company for 2025 was 1,345 million RMB, with a remarkable year-on-year increase of 358.09% [7] - The company’s revenue is expected to reach 63,242 million RMB in 2026, with a growth rate of 22.90% [6] - The projected net profit for 2026 is 2,017 million RMB, indicating a growth rate of 49.99% [6] Business Expansion and Strategy - As of the end of 2025, the company operated 18,314 snack retail stores across 30 provinces, indicating a robust expansion strategy [7] - The company is focusing on enhancing supply chain resilience, building a smart logistics system, and improving brand recognition, which are expected to drive operational efficiency and sustainable profitability [7] Industry Outlook - The edible fungus industry is showing signs of recovery, with a revenue of 60.2 million RMB in 2025, marking an 11.81% year-on-year growth [7] - The company is well-positioned to leverage its supply chain advantages and improve profitability as it continues to expand its snack retail operations [7]

Group 1 - The investment rating for the company is to "pay attention" [2][3] - The company is a national-level "little giant" in micro-special motors, with a net profit attributable to the parent company of 67.77 million yuan for Q1-Q3 2025, representing a year-on-year increase of 30% [12][39] - The company specializes in the research, production, and sales of micro-special motors, primarily used in cleaning appliances such as vacuum cleaners, and has established stable business relationships with numerous manufacturers [12][36] Group 2 - The global micro-special motor market size reached 49.3 billion USD in 2024 and is expected to grow to 66.4 billion USD by 2029, with a compound annual growth rate (CAGR) of 5.76% [44][48] - The domestic micro-special motor market in China is projected to grow from 16.7 billion USD in 2020 to 34.3 billion USD by 2029, with a CAGR of 8.29% [51][53] - The company plans to invest 490 million yuan in expanding production capacity for permanent magnet brushless motors and systems, aiming for an annual production capacity of 12 million sets of these motors [10][11]

Investment Rating - The report assigns a "Buy" rating for Junshi Biosciences, indicating strong innovation capabilities and potential for significant value realization in the near future [5][8]. Core Insights - Junshi Biosciences, established in December 2012, is a leading innovative biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company has a robust pipeline and a solid foundation in its existing products, particularly the PD-1 monoclonal antibody, Toripalimab, which is expected to generate substantial revenue growth [7][10]. - The company is expected to achieve significant revenue growth, with projected revenues of RMB 33.98 billion, RMB 45.50 billion, and RMB 57.80 billion for the years 2026 to 2028, respectively. The net profit is forecasted to improve from a loss of RMB 4.97 billion in 2026 to a profit of RMB 7.64 billion by 2028 [6][8]. Summary by Relevant Sections Market Performance - The closing price of Junshi Biosciences is RMB 31.29, with a total market capitalization of RMB 32,125.13 million and a total share capital of 1,026.69 million shares. The company has an asset-liability ratio of 51.09% and a net asset value per share of RMB 5.87 [3]. Revenue and Profit Forecast - Revenue projections for Junshi Biosciences are as follows: RMB 1,948 million in 2024, RMB 2,498 million in 2025, RMB 3,398 million in 2026, RMB 4,550 million in 2027, and RMB 5,780 million in 2028, with corresponding year-on-year growth rates of 29.67%, 28.23%, 36.00%, 33.89%, and 27.06% [6][8]. - The forecasted net profit for the same years is expected to be a loss of RMB 1,281 million in 2024, a loss of RMB 875 million in 2025, a loss of RMB 497 million in 2026, a profit of RMB 258 million in 2027, and a profit of RMB 764 million in 2028, with significant improvements in profitability anticipated [6][8]. Product Pipeline and Innovation - Junshi Biosciences has a strong pipeline with several late-stage clinical candidates expected to enter the market soon. Key products include JS207, a PD-1/VEGF bispecific antibody, and JS107, a CLDN 18.2 ADC, both of which show promising clinical data and potential for rapid approval [10][28]. - The company’s lead product, Toripalimab, is expected to generate sales of RMB 20.68 billion in 2025, reflecting a year-on-year growth of 37.72%. The product has received multiple approvals for various indications and is positioned to capture significant market share [21][17]. Management and Strategy - The management team of Junshi Biosciences is experienced in drug development and commercialization, with key appointments aimed at enhancing the company's strategic direction and operational efficiency. The team includes professionals with extensive backgrounds in oncology and biopharmaceuticals [14][15]. Competitive Landscape - Junshi Biosciences is well-positioned in the competitive landscape of innovative biopharmaceuticals, particularly in the PD-1/VEGF dual antibody space, which has seen significant investment and interest from global pharmaceutical companies [40][41].

Investment Rating - The investment rating for the construction and decoration industry is "Positive" (maintained) [4] Core Viewpoints - In January and February 2026, infrastructure fixed asset investment reached 1.88 trillion yuan, a year-on-year increase of 11.40%. Key sectors include electricity, heat, gas, and water supply, which saw a growth of 13.10% year-on-year [5][13] - The report suggests that infrastructure investment logic may gradually shift from traditional "stabilizing growth" to structural investments that serve national strategies and security needs. Key focus areas include clean energy projects and energy security [9] Summary by Sections Infrastructure Investment - Infrastructure investment in January and February 2026 totaled 1.88 trillion yuan, with a year-on-year growth of 11.40%. Transportation and storage sectors grew by 9.10%, while electricity and water supply sectors grew by 13.10% [5][13] - The report anticipates continued high growth in infrastructure investment due to ongoing "stabilizing investment" policies and the acceleration of major projects [5][13] Market Performance - The Shanghai Composite Index fell by 3.38%, while the Shenzhen Component Index decreased by 2.90%. The construction and decoration index dropped by 6.25% [8][27] - Among individual stocks, notable gainers included Yaxiang Integration (+31.31%) and Dongfang Xinneng (+27.94%) [8][27] Company Dynamics - New special bonds issued this week amounted to 1140.47 billion yuan, with a cumulative issuance of 10,486.60 billion yuan, reflecting a year-on-year increase of 50.82% [7][34] - The report highlights significant project announcements, including the construction of 350 key projects in the Chengdu-Chongqing economic circle, with an expected annual investment of 499.2 billion yuan [18]

Fixed Income/Banking - Short-term credit continues to show strong performance, with AA+ steel and media industry credit spreads significantly compressing compared to last week, while AAA defense and military industry credit spreads have slightly widened [2][8] - The government work report for 2026 indicates a continuation of moderately loose monetary policy, leading to an overall optimistic expectation for liquidity, despite the ongoing "asset shortage" in the credit bond market [2][8] - The monthly open scale of 2026 M3 amortized open-end bond funds reached 126 billion yuan, supporting 3-5 year credit bond allocations [2][8] Real Estate - The real estate sector experienced a decline of 4.2% this week, with new home transactions in 42 key cities totaling 2.1 million square meters, a month-on-month increase of 11.1% [10][12] - Nanjing has introduced six policies to stabilize the real estate market, including encouraging housing consumption through "old for new" exchanges and reducing purchasing costs [13] - The first two months of 2026 saw a 6.1% increase in electricity consumption, indicating a potential recovery in the real estate market [37] Machinery/Building Materials - The focus is on low-volatility safe assets and potential beneficiaries of rising costs, with the cement sector expected to reach a turning point in mid-year [17][18] - The central urban work conference has initiated a new era of urban renewal, with an average annual underground pipeline investment expected to reach 1 trillion yuan during the 14th Five-Year Plan [18] - Upstream raw material price increases may lead to differentiated performance across various segments, with recommendations to focus on the paint and waterproofing industries [18] Transportation - The shipping industry is advised to focus on oil transportation due to favorable fundamentals, while the express delivery sector is experiencing a "de-involution" trend that supports price increases and enhances profitability [20][33] - The express delivery industry saw a 7.1% year-on-year increase in volume for January-February 2026, with significant differentiation in market share among major players [25][26] - The shipping market is expected to benefit from ongoing geopolitical tensions and supply chain diversification, with recommendations to focus on companies like China Merchants Energy and COSCO Shipping [34] Public Utilities and Environmental Protection - Electricity consumption increased by 6.1% in the first two months of 2026, with expectations for annual growth of 5%-6% [37] - The domestic energy storage sector remains robust, with lithium-ion battery production increasing by 84% in early 2026, driven by improved commercial models and energy security projects [37] - Stable pricing for pipeline gas contracts by PetroChina for 2026-2027 is expected to enhance profitability in the gas trading sector [37]

Investment Rating - The investment rating for the nuclear power sector is "Positive" (maintained) [4] Core Insights - The recent announcement by the Liaoning Provincial Development and Reform Commission regarding the participation of nuclear power units in market transactions is expected to enhance corporate profitability and valuation. This includes the establishment of a sustainable pricing settlement mechanism for nuclear power and an off-market price difference settlement mechanism [4] - The policy aims to stabilize nuclear power pricing, with 2026 mechanism electricity volume set at 80% of the monthly grid electricity volume, excluding specific hours, and a mechanism price of 0.3798 yuan/kWh [4] - The introduction of this pricing mechanism is anticipated to be extended to other provinces, with early indications of similar mechanisms in Guangxi [4] - The report estimates that a 1 cent increase in the electricity price could lead to a net profit increase of 8 million yuan for China General Nuclear Power and 6 million yuan for China National Nuclear Power, representing 7% of their respective net profits for 2024 [4] - The stability of electricity prices and growth in nuclear power installations reaffirm the investment value in nuclear power, with recommendations to focus on China General Nuclear Power and China National Nuclear Power [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights that the domestic computing power market remains strong, and rapid growth in Southeast Asia is expected to drive performance to new heights [5] - The company achieved a revenue of HKD 97.63 billion in 2025, representing a year-on-year growth of 9.6%, and a net profit of HKD 1.35 billion, up 28.7% year-on-year [7] - The company is positioned as a leading technology service platform in the Asia-Pacific region, benefiting from the AI wave and digital transformation of enterprises [7] Financial Performance Summary - Revenue projections for the company are as follows: - 2024: HKD 89.09 billion - 2025: HKD 97.63 billion - 2026E: HKD 111.08 billion (growth rate of 13.8%) - 2027E: HKD 125.36 billion (growth rate of 12.9%) - 2028E: HKD 141.00 billion (growth rate of 12.5%) [6] - Net profit projections are as follows: - 2024: HKD 1.05 billion - 2025: HKD 1.35 billion - 2026E: HKD 1.61 billion (growth rate of 19.0%) - 2027E: HKD 1.92 billion (growth rate of 18.9%) - 2028E: HKD 2.29 billion (growth rate of 19.4%) [6] - The company’s return on equity (ROE) is projected to increase from 12.2% in 2024 to 16.4% in 2028 [6] Business Segments and Growth Drivers - The company’s three core business segments all achieved growth: - Enterprise systems business grew by 2.3% to HKD 53.53 billion, accounting for 54.8% of total revenue - Consumer electronics segment revenue surged by 18.9% to HKD 39.01 billion, making up 40% of total revenue - Cloud computing segment grew by 29.1% to HKD 5.08 billion, although it only represents 5.2% of total revenue [7] - The Southeast Asian market showed significant performance, with revenue increasing by 16.6% to HKD 35.75 billion, now accounting for 36.6% of total revenue [7] Strategic Initiatives - The company is building a "domestic + overseas" dual-track computing power ecosystem, with a focus on AI-related performance growth of 27% year-on-year [7] - The company has established partnerships with major players like Huawei and has successfully implemented key projects in the AI infrastructure sector [7] - The company is becoming a crucial platform for Chinese tech companies expanding overseas, with significant growth in its Southeast Asian operations [7]